Chemours Company (NYSE: CC)’s stock price has plunge by -0.55relation to previous closing price of 27.15. Nevertheless, the company has seen a -6.48% plunge in its stock price over the last five trading sessions. https://feeds.newsfilecorp.com reported 2024-05-20 that DEADLINE TODAY: The Schall Law Firm Encourages Investors in The Chemours Company with Losses to Contact the Firm May 20, 2024 12:53 PM EDT | Source: Schall Law Firm Los Angeles, California–(Newsfile Corp. – May 20, 2024) – The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company’s securities between February 10, 2023 and February 28, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before May 20, 2024. If you are a shareholder who suffered a loss, click here to participate.We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com.The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Chemours’ management team manipulated targets for free cash flow to maximize executive compensation under its Annual Incentive Plans and Long-Term Incentive Plans. The Company failed to maintain appropriate controls over financial reporting. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Chemours, investors suffered damages.Join the case to recover your losses.The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.CONTACT:The Schall Law FirmBrian Schall, Esq.,www.schallfirm.comOffice: 310-301-3335info@schallfirm.comSOURCE: The Schall Law FirmTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/209850 SOURCE: Schall Law Firm Learn more about Bill C-18 and how it will affect Canadian users when viewing news online.
Is It Worth Investing in Chemours Company (NYSE: CC) Right Now?
Additionally, the 36-month beta value for CC is 1.83. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CC is 147.03M and currently, short sellers hold a 3.90% ratio of that float. The average trading volume of CC on May 24, 2024 was 2.02M shares.
CC’s Market Performance
CC’s stock has seen a -6.48% decrease for the week, with a -0.30% drop in the past month and a -8.41% fall in the past quarter. The volatility ratio for the week is 2.43%, and the volatility levels for the past 30 days are at 3.06% for Chemours Company The simple moving average for the past 20 days is -2.90% for CC’s stock, with a -5.51% simple moving average for the past 200 days.
Analysts’ Opinion of CC
Many brokerage firms have already submitted their reports for CC stocks, with BMO Capital Markets repeating the rating for CC by listing it as a “Outperform.” The predicted price for CC in the upcoming period, according to BMO Capital Markets is $34 based on the research report published on April 09, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see CC reach a price target of $21, previously predicting the price at $37. The rating they have provided for CC stocks is “Neutral” according to the report published on March 05th, 2024.
BMO Capital Markets gave a rating of “Underperform” to CC, setting the target price at $19 in the report published on February 29th of the current year.
CC Trading at -1.65% from the 50-Day Moving Average
After a stumble in the market that brought CC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.86% of loss for the given period.
Volatility was left at 3.06%, however, over the last 30 days, the volatility rate increased by 2.43%, as shares sank -0.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.60% upper at present.
During the last 5 trading sessions, CC fell by -6.48%, which changed the moving average for the period of 200-days by -26.77% in comparison to the 20-day moving average, which settled at $27.80. In addition, Chemours Company saw -14.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CC starting from Newman Mark, who purchase 7,661 shares at the price of $34.63 back on Jun 09 ’23. After this action, Newman Mark now owns 266,955 shares of Chemours Company, valued at $265,300 using the latest closing price.
Scarborough Alvenia, the SVP Corp Communications & CBO of Chemours Company, sale 5,125 shares at $32.30 during a trade that took place back on Jun 09 ’23, which means that Scarborough Alvenia is holding 13,890 shares at $165,537 based on the most recent closing price.
Stock Fundamentals for CC
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.21 for the gross margin
The net margin for Chemours Company stands at -0.06. The total capital return value is set at -0.03. Equity return is now at value -33.35, with -4.23 for asset returns.
Based on Chemours Company (CC), the company’s capital structure generated 0.85 points at debt to capital in total, while cash flow to debt ratio is standing at 0.09. The debt to equity ratio resting at 5.66. The interest coverage ratio of the stock is -1.66.
Currently, EBITDA for the company is 220.0 million with net debt to EBITDA at 76.39. When we switch over and look at the enterprise to sales, we see a ratio of 1.29. The receivables turnover for the company is 7.38for trailing twelve months and the total asset turnover is 0.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.61.
Conclusion
In conclusion, Chemours Company (CC) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
